Encompass Health Co. (NYSE:EHC) Short Interest Update

Encompass Health Co. (NYSE:EHCGet Rating) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,610,000 shares, a decrease of 23.9% from the March 15th total of 3,430,000 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average daily volume of 902,200 shares, the short-interest ratio is presently 2.9 days.

EHC has been the topic of a number of research reports. Credit Suisse Group dropped their target price on shares of Encompass Health from $84.00 to $77.00 in a report on Thursday, February 3rd. Truist Financial increased their price objective on shares of Encompass Health from $78.00 to $85.00 in a report on Thursday, April 7th. Zacks Investment Research raised shares of Encompass Health from a “sell” rating to a “hold” rating and set a $76.00 price objective on the stock in a report on Monday, April 11th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Encompass Health from $95.00 to $80.00 in a report on Thursday, January 20th. Finally, Raymond James dropped their price objective on shares of Encompass Health from $90.00 to $80.00 and set a “strong-buy” rating on the stock in a report on Monday, February 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $83.89.

EHC traded down $1.12 on Monday, reaching $71.41. The company had a trading volume of 544,692 shares, compared to its average volume of 883,918. The company has a fifty day moving average of $68.61 and a 200-day moving average of $65.59. The company has a market capitalization of $7.10 billion, a P/E ratio of 17.47, a PEG ratio of 2.54 and a beta of 0.99. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.38. Encompass Health has a one year low of $56.31 and a one year high of $89.68.

Encompass Health (NYSE:EHCGet Rating) last announced its earnings results on Tuesday, February 1st. The company reported $0.97 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.09). The company had revenue of $11.32 billion during the quarter, compared to the consensus estimate of $1.31 billion. Encompass Health had a net margin of 8.05% and a return on equity of 19.20%. The business’s quarterly revenue was up 832.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. Research analysts predict that Encompass Health will post 4.11 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 18th. Stockholders of record on Friday, April 1st will be given a dividend of $0.28 per share. The ex-dividend date is Thursday, March 31st. This represents a $1.12 annualized dividend and a dividend yield of 1.57%. Encompass Health’s dividend payout ratio (DPR) is 27.25%.

Several large investors have recently bought and sold shares of EHC. Norges Bank bought a new position in shares of Encompass Health during the 4th quarter valued at about $61,794,000. Baupost Group LLC MA purchased a new stake in Encompass Health during the fourth quarter valued at about $46,733,000. Canyon Capital Advisors LLC purchased a new stake in Encompass Health during the third quarter valued at about $47,575,000. Wellington Management Group LLP lifted its stake in Encompass Health by 5.8% during the third quarter. Wellington Management Group LLP now owns 8,181,371 shares of the company’s stock valued at $613,929,000 after buying an additional 450,688 shares in the last quarter. Finally, Glenview Capital Management LLC purchased a new stake in Encompass Health during the third quarter valued at about $30,067,000. Institutional investors own 92.35% of the company’s stock.

About Encompass Health (Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Further Reading

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.